A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer (ASPEN-06)

A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-overexpressing gastric/gastroesophageal junction adenocarcinoma - ASPEN-06

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220162

Enrollment

Registered

2022-06-25

Start date

2022-08-23

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric/gastroesophageal junction adenocarcinoma

Interventions

ALX148 30 mg/kg Q2W as an intravenous infusion on Days 1 and 15 of a 28-day cycle. Trastuzumab will be administered at an initial dose of 6 mg/kg administered as an intravenous infusion, followed by 4

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line) -Adequate Bone Marrow Function. -Adequate Renal and Liver Function. -Adequate Performance Status.

Exclusion criteria

Exclusion criteria: -Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids. -Prior treatment with any anti-CD47 or anti-SIRP alpha agent. -Prior treatment with ramucirumab.

Design outcomes

Primary

Measure	Time frame
Phase 2: -Percentage of patients with objective response per RECIST 1.1 Phase 3: -Overall Survival	—

Countries

BELGIUM, CZECH REPUBLIC, FRANCE, ITALY, Japan, SINGAPORE, SOUTH KOREA, SPAIN, TAIWAN, UNITED KINGDOM, UNITED STATES

Contacts

Public Contactcontact Clinical

ICON Clinical Research GK

ICONCR-Chiken@iconplc.com+81-6-4560-2001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026